Home/Pipeline/MBT Oncology Program

MBT Oncology Program

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication

Oncology (unspecified)

Phase

Pre-clinical

Status

Active

Company

Ionic Pharmaceuticals

About Ionic Pharmaceuticals

Ionic Pharmaceuticals is a private, preclinical-stage biotech developing a novel nanoparticle drug delivery platform with a claimed 50x improvement in tumor accumulation efficiency. The company, a Boston University spin-out, is applying its materials science expertise across two initial sectors: oncology drug delivery and wound care. Led by a team with prior drug development and commercialization success, including a co-inventor of the blockbuster drug Abraxane, Ionic is currently funded by NIH grants and awards as it works towards commercialization.

View full company profile

Therapeutic Areas

Oncology Wound Care

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active
DDX3 Inhibitor (Oncology)	Lead Discovery Siena	Discovery	Active